Hepatitis Diagnostic Tests Market Report 2026

The hepatitis diagnostic tests market size has grown strongly in recent years. It will grow from $4.93 billion in 2025 to $5.21 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to expansion of hepatitis screening programs, increased laboratory testing volumes, rising awareness of viral hepatitis, improved access to diagnostic infrastructure, availability of standardized testing protocols.

The hepatitis diagnostic tests market size is expected to see strong growth in the next few years. It will grow to $6.72 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing demand for decentralized diagnostics, rising investments in advanced molecular testing, expansion of home-based testing solutions, growing focus on early disease detection, increased adoption in low-resource settings. Major trends in the forecast period include increasing adoption of rapid diagnostic tests, rising use of molecular diagnostic technologies, growing integration of automated laboratory systems, expansion of point-of-care testing solutions, enhanced focus on early and accurate diagnosis.

The increasing number of blood transfusions and donations is expected to drive the growth of the hepatitis diagnostic test market in the coming years. Blood transfusions and donations are interconnected processes in which individuals voluntarily provide blood, which is then collected, tested, and administered to patients needing additional blood components to treat medical conditions or replace blood lost due to surgery, accidents, or illness. Hepatitis diagnostic tests are used to thoroughly screen blood prior to donation or transfusion to ensure patient safety. For example, according to the Royal College of Pathologists, a UK-based organization, blood transfusion is the most frequently performed procedure for hospitalized patients, with nearly 2 million blood components issued and transfused in England annually, at a cost of over £300 million ($390.69 million) as of August 2023. Therefore, the rising number of blood transfusions and donations is driving the hepatitis diagnostic test market.

Leading companies in the hepatitis diagnostic test market are developing innovative automated immunoassays, such as Elecsys HCV Duo, to improve diagnostic accuracy and efficiency. Automated immunoassays use specialized instruments and automation systems to handle all stages of the immunoassay process, including sample handling, reagent mixing, incubation, detection, and result calculation. For instance, in July 2023, Roche Diagnostics India launched Elecsys HCV Duo, India’s first fully automated immunoassay enabling simultaneous and independent assessment of hepatitis C virus (HCV) antigen and antibody levels from a single plasma or serum sample. This technology allows single-specimen testing, streamlines the diagnostic process, reduces the number of patient visits for additional tests, and eases the burden on the healthcare system.

In October 2024, The Bank of Nova Scotia, a Canada-based company, acquired Bio-Rad Laboratories for an undisclosed amount. Through this acquisition, The Bank of Nova Scotia aims to expand its portfolio by leveraging Bio-Rad Laboratories’ expertise in hepatitis diagnostic testing products and services. Bio-Rad Laboratories Inc., a US-based company, specializes in providing diagnostic testing for hepatitis.

Major companies operating in the hepatitis diagnostic tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Roche Diagnostics, Quest Diagnostics Incorporated, Grifols S.A, Hologic Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Co. Ltd., QIAGEN N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Luminex Corporation, Fujirebio Diagnostics Inc., Trivitron Healthcare Private Limited, Trinity Biotech plc, MP Biomedicals LLC, R-Biopharm AG, Creative Diagnostics, InBios International Inc., Dia.Pro Diagnostic Bioprobes srl, DIALAB GmbH.

North America was the largest region in the hepatitis diagnostic tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis diagnostic tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis diagnostic tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hepatitis diagnostic tests market by increasing costs of imported reagents, test kits, analyzers, and electronic diagnostic components. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported testing technologies, while Asia-Pacific faces higher costs for equipment manufacturing and exports. These tariffs are raising testing costs and delaying laboratory upgrades. At the same time, they are supporting local diagnostic manufacturing, regional reagent production, and increased investment in domestic diagnostic innovation.

The hepatitis diagnostic tests market research report is one of a series of new reports that provides hepatitis diagnostic tests market statistics, including hepatitis diagnostic tests industry global market size, regional shares, competitors with a hepatitis diagnostic tests market share, detailed hepatitis diagnostic tests market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis diagnostic tests industry. This hepatitis diagnostic tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis diagnostic tests are medical examinations and laboratory procedures designed to detect and diagnose hepatitis infections, including hepatitis A, B, C, D, and E. These tests identify the presence of hepatitis viruses or specific antibodies in a patient’s blood or other bodily fluids to confirm infection and assess its type, severity, and progression.

The main types of hepatitis diagnostic tests include blood tests, imaging tests, and liver biopsy. Blood tests involve analyzing samples from a patient to measure levels of blood constituents such as cells, proteins, enzymes, hormones, antibodies, and other chemicals. Technologies used in these tests include enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification tests, and others. These tests are utilized by various end-users, including hospitals, diagnostic laboratories, blood banks, and additional healthcare facilities.

The hepatitis diagnostic test market consists of revenues earned by entities by providing diagnostic services such as liver ultrasound, computerized tomography (CT) scans, and antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis diagnostic test market also includes sales of laboratory equipment, reagents, and assay components that are used in providing hepatitis diagnostic test services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.